Safety and Effectiveness of Mosaic for the Treatment of Midface Volume Deficit
NCT07710443
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to study whether the Mosaic Injectable Dermal Implant is a safe and effective treatment for age-related midface volume deficit in adults who are at least 22 years of age. The main questions it aims to answer are: What medical problems do participants have when receiving Mosaic over the 12 months following treatment. How much does Mosaic improve the midface volume at 6 months post-treatment. Participants will: Receive injections to the midface to correct volume deficit.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Midface Volume Deficit
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Helios Aesthetics Inc.
- Last updated on ClinicalTrials.gov
- August 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Weinkle Dermatology · Bradenton, FL
- Skin Research Institute LLC · Coral Gables, FL
Massachusetts · 1
- SkinCare Physicians · Chestnut Hill, MA
New York · 1
- Skin Fluence LLC · Huntington Station, NY
Pennsylvania · 1
- Bloom Facial Plastic & Aesthetic Surgery · Bryn Mawr, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.